Genmab A/S

ISIN DK0010272202

 | 

WKN 565131

 

Overview

Quote

Description

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Show more Show less
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Denmark

Chart

Financials

Key metrics

Market capitalisation, EUR 10,940.93 m
EPS, EUR 16.44
P/B ratio 2.21
P/E ratio 10.43
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 2,886.80 m
Net income, EUR 1,051.94 m
Profit margin 36.44%

What ETF is Genmab A/S in?

There are 237 ETFs which contain Genmab A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of Genmab A/S is the Xtrackers Nordic Net Zero Pathway Paris Aligned UCITS ETF 1C.

Performance

Returns overview

YTD -11.47%
1 month -7.33%
3 months -11.30%
6 months -16.90%
1 year -37.79%
3 years -48.42%
5 years -15.05%
Since inception (MAX) +13.40%
2024 -33.56%
2023 -28.63%
2022 +18.98%
2021 -0.77%

Monthly returns in a heat map

Risk

Risk metrics in this section:
 
  • Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
  • Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
  • Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
ETF returns include dividend payments (if applicable).
Show more Show less

Risk overview

Volatility 1 year 29.56%
Volatility 3 years 30.31%
Volatility 5 years 31.27%
Return per risk 1 year -1.28
Return per risk 3 years -0.65
Return per risk 5 years -0.10
Maximum drawdown 1 year -40.39%
Maximum drawdown 3 years -63.16%
Maximum drawdown 5 years -63.16%
Maximum drawdown since inception -63.16%

Rolling 1 year volatility

— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.